Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O94788

UPID:
AL1A2_HUMAN

ALTERNATIVE NAMES:
Aldehyde dehydrogenase family 1 member A2; Retinaldehyde-specific dehydrogenase type 2

ALTERNATIVE UPACC:
O94788; B3KY52; B4DZR2; F5H2Y9; H0YM00; Q2PJS6; Q8NHQ4; Q9UBR8; Q9UFY0

BACKGROUND:
Retinal dehydrogenase 2, recognized for its specific activity on all-trans-retinal and all-trans-13,14-dihydroretinal, catalyzes their conversion to all-trans-retinoate and all-trans-13,14-dihydroretinoate, respectively. This process is integral to retinoate signaling, a key regulator of gene transcription and meiosis initiation. The enzyme's ability to metabolize various aldehydes, albeit with differing efficiencies, highlights its versatility and importance in biological systems.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Diaphragmatic hernia 4, characterized by congenital diaphragmatic defects and cardiovascular malformations, Retinal dehydrogenase 2 presents a promising target for developing novel therapeutic approaches. Exploring the enzyme's function and its pathways offers a pathway to innovative treatments for complex congenital conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.